Thompson JA - Search Results

1

Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438).

Thompson JA, Fisher RI, Leblanc M, Forman SJ, Press OW, Unger JM, Nademanee AP, Stiff PJ, Petersdorf SH, Fefer A. Thompson JA, et al. Blood. 2008 Apr 15;111(8):4048-54. doi: 10.1182/blood-2007-09-111708. Epub 2008 Feb 6. Blood. 2008. PMID: 18256325 Free PMC article. Clinical Trial.

2

Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma.

Thompson JA, Shulman KL, Benyunes MC, Lindgren CG, Collins C, Lange PH, Bush WH Jr, Benz LA, Fefer A. Thompson JA, et al. J Clin Oncol. 1992 Jun;10(6):960-8. doi: 10.1200/JCO.1992.10.6.960. J Clin Oncol. 1992. PMID: 1588376 Clinical Trial.

3

Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies.

Higuchi CM, Thompson JA, Petersen FB, Buckner CD, Fefer A. Higuchi CM, et al. Among authors: thompson ja. Blood. 1991 Jun 15;77(12):2561-8. Blood. 1991. PMID: 2043762 Free article.

4

Enhancement by interleukin 4 of interleukin 2- or antibody-induced proliferation of lymphocytes from interleukin 2-treated cancer patients.

Treisman J, Higuchi CM, Thompson JA, Gillis S, Lindgren CG, Kern DE, Ridell SR, Greenberg PD, Fefer A. Treisman J, et al. Among authors: thompson ja. Cancer Res. 1990 Feb 15;50(4):1160-4. Cancer Res. 1990. PMID: 2153452

5

Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies.

Higuchi CM, Thompson JA, Cox T, Lindgren CG, Buckner CD, Fefer A. Higuchi CM, et al. Among authors: thompson ja. Cancer Res. 1989 Oct 15;49(20):5509-13. Cancer Res. 1989. PMID: 2477142

6

Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro.

Higuchi CM, Thompson JA, Lindgren CG, Gillis S, Widmer MB, Kern DE, Fefer A. Higuchi CM, et al. Among authors: thompson ja. Cancer Res. 1989 Dec 1;49(23):6487-92. Cancer Res. 1989. PMID: 2479463

7

Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects.

Thompson JA, Lee DJ, Kidd P, Rubin E, Kaufmann J, Bonnem EM, Fefer A. Thompson JA, et al. J Clin Oncol. 1989 May;7(5):629-37. doi: 10.1200/JCO.1989.7.5.629. J Clin Oncol. 1989. PMID: 2651578

8

Very low dose alpha-2b interferon for the treatment of hairy cell leukemia.

Thompson JA, Kidd P, Rubin E, Fefer A. Thompson JA, et al. Blood. 1989 May 1;73(6):1440-3. Blood. 1989. PMID: 2713488 Free article.

9

Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells.

Thompson JA, Lee DJ, Lindgren CG, Benz LA, Collins C, Shuman WP, Levitt D, Fefer A. Thompson JA, et al. Cancer Res. 1989 Jan 1;49(1):235-40. Cancer Res. 1989. PMID: 2783243

10

Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation.

Thompson JA, Lee DJ, Lindgren CG, Benz LA, Collins C, Levitt D, Fefer A. Thompson JA, et al. J Clin Oncol. 1988 Apr;6(4):669-78. doi: 10.1200/JCO.1988.6.4.669. J Clin Oncol. 1988. PMID: 3258631

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,070 results

Search Page